• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 10-Q filed by CeriBell Inc.

    5/8/25 4:36:43 PM ET
    $CBLL
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $CBLL alert in real time by email

    Unavailable

    Get the next $CBLL alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $CBLL

    DatePrice TargetRatingAnalyst
    6/24/2025$30.00Buy
    BTIG Research
    4/4/2025$32.00Buy
    Ladenburg Thalmann
    11/5/2024$32.00Buy
    BofA Securities
    11/5/2024$30.00Buy
    Canaccord Genuity
    11/5/2024$32.00Overweight
    JP Morgan
    11/5/2024$31.00Buy
    TD Cowen
    11/5/2024Outperform
    William Blair
    More analyst ratings

    $CBLL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President and CEO Chao Xingjuan sold $442,500 worth of shares (25,000 units at $17.70) and exercised 25,000 shares at a strike of $2.24, decreasing direct ownership by 0.03% to 776,022 units (SEC Form 4)

      4 - Ceribell, Inc. (0001861107) (Issuer)

      7/9/25 2:49:17 PM ET
      $CBLL
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Director Robertson Rebecca B sold $330,961 worth of shares (18,633 units at $17.76), decreasing direct ownership by 65% to 10,042 units (SEC Form 4)

      4 - Ceribell, Inc. (0001861107) (Issuer)

      6/20/25 12:31:36 PM ET
      $CBLL
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Director Robertson Rebecca B was granted 8,828 shares, exercised 20,000 shares at a strike of $3.61 and sold $342,800 worth of shares (20,000 units at $17.14), increasing direct ownership by 44% to 28,675 units (SEC Form 4)

      4 - Ceribell, Inc. (0001861107) (Issuer)

      6/17/25 7:52:14 PM ET
      $CBLL
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $CBLL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • BTIG Research initiated coverage on CeriBell with a new price target

      BTIG Research initiated coverage of CeriBell with a rating of Buy and set a new price target of $30.00

      6/24/25 8:00:31 AM ET
      $CBLL
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Ladenburg Thalmann initiated coverage on CeriBell with a new price target

      Ladenburg Thalmann initiated coverage of CeriBell with a rating of Buy and set a new price target of $32.00

      4/4/25 8:27:23 AM ET
      $CBLL
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • BofA Securities initiated coverage on CeriBell with a new price target

      BofA Securities initiated coverage of CeriBell with a rating of Buy and set a new price target of $32.00

      11/5/24 7:25:17 AM ET
      $CBLL
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $CBLL
    SEC Filings

    See more
    • CeriBell Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Ceribell, Inc. (0001861107) (Filer)

      7/7/25 5:21:34 PM ET
      $CBLL
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • CeriBell Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

      8-K - Ceribell, Inc. (0001861107) (Filer)

      6/20/25 12:45:39 PM ET
      $CBLL
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 144 filed by CeriBell Inc.

      144 - Ceribell, Inc. (0001861107) (Subject)

      6/18/25 1:23:53 PM ET
      $CBLL
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $CBLL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Tpg Gp A, Llc converted options into 3,587,154 shares and bought $6,464,556 worth of shares (380,268 units at $17.00) (SEC Form 4)

      4 - Ceribell, Inc. (0001861107) (Issuer)

      10/17/24 4:14:38 PM ET
      $CBLL
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Director Tammenoms Bakker Juliet was granted 6,618 shares, converted options into 2,140,600 shares and bought $4,032,978 worth of shares (237,234 units at $17.00) (SEC Form 4)

      4 - Ceribell, Inc. (0001861107) (Issuer)

      10/16/24 4:18:06 PM ET
      $CBLL
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $CBLL
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Ceribell to Participate in the Canaccord Genuity 45th Annual Growth Conference

      SUNNYVALE, Calif., July 29, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (NASDAQ:CBLL) ("Ceribell"), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that Jane Chao, Ph.D., CEO and Co-founder, will present at the upcoming Canaccord Genuity 45th Annual Growth Conference. The presentation will take place on Tuesday, August 12, 2025, at 11:00 a.m. Pacific Standard Time / 2:00 p.m. Eastern Standard Time.  Event: Canaccord Genuity 45th Annual Growth ConferenceDate: Tuesday, August 12, 2025Time: 11:00 a.m. PST / 2:00 p.m. EST A live and archived webcast of the presentation will be available in the "In

      7/29/25 4:05:00 PM ET
      $CBLL
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Ceribell to Report Second Quarter 2025 Financial Results on August 5, 2025

      SUNNYVALE, Calif., July 22, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (NASDAQ:CBLL) ("Ceribell"), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that it will release financial results for the second quarter of 2025 after the close of trading on Tuesday, August 5, 2025. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET on August 5, 2025. Investors interested in listening to the conference call may do so by dialing (800) 715-9871 for domestic callers or (646) 307-1963 for international callers and providing access code 7468193.

      7/22/25 4:05:00 PM ET
      $CBLL
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Ceribell Files Complaints Against Natus Medical Incorporated with the U.S. International Trade Commission and Federal Court in Delaware

      SUNNYVALE, Calif., July 07, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (NASDAQ:CBLL) ("Ceribell"), a leading medical technology company transforming the diagnosis and management of patients with serious neurological conditions, announced today that it filed complaints against Natus Medical Incorporated and related subsidiaries ("Natus"), alleging patent infringement and unfair competition. A complaint was filed with the U.S. International Trade Commission (USITC), an independent, non-partisan agency that investigates and makes determinations in proceedings involving imports claimed to violate U.S. intellectual property rights.  Ceribell has requested that the USITC investigate its claims and

      7/7/25 4:42:49 PM ET
      $CBLL
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $CBLL
    Financials

    Live finance-specific insights

    See more
    • Ceribell to Report Second Quarter 2025 Financial Results on August 5, 2025

      SUNNYVALE, Calif., July 22, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (NASDAQ:CBLL) ("Ceribell"), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that it will release financial results for the second quarter of 2025 after the close of trading on Tuesday, August 5, 2025. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET on August 5, 2025. Investors interested in listening to the conference call may do so by dialing (800) 715-9871 for domestic callers or (646) 307-1963 for international callers and providing access code 7468193.

      7/22/25 4:05:00 PM ET
      $CBLL
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Ceribell Reports First Quarter 2025 Financial Results

      SUNNYVALE, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (NASDAQ:CBLL) ("Ceribell"), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today reported financial results for the quarter ended March 31, 2025. First Quarter 2025 & Recent Highlights Reported total revenue of $20.5 million in the first quarter of 2025, a 42% increase compared to the same period in 2024Ended the quarter with 558 total active accounts Achieved gross margin of 88% in the first quarter of 2025Received U.S. Food and Drug Administration 510(k) clearance for expansion of Clarity™ algorithm indication, becoming the first s

      5/8/25 4:05:00 PM ET
      $CBLL
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Ceribell to Report First Quarter 2025 Financial Results on May 8, 2025

      SUNNYVALE, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (NASDAQ:CBLL) ("Ceribell"), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that it will release financial results for the first quarter of 2025 after the close of trading on Thursday, May 8, 2025. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET on May 8, 2025. Investors interested in listening to the conference call may do so by dialing (800) 715-9871 for domestic callers or (646) 307-1963 for international callers and providing access code 7370458. A li

      4/24/25 4:05:00 PM ET
      $CBLL
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $CBLL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by CeriBell Inc.

      SC 13G - Ceribell, Inc. (0001861107) (Subject)

      11/7/24 9:24:55 AM ET
      $CBLL
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13D filed by CeriBell Inc.

      SC 13D - Ceribell, Inc. (0001861107) (Subject)

      10/22/24 4:20:26 PM ET
      $CBLL
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $CBLL
    Leadership Updates

    Live Leadership Updates

    See more
    • Ceribell Appoints Kristie Rodenbush as Chief People Officer and Brian Price as Senior Vice President of Marketing

      —Ms. Rodenbush to lead hiring and talent development initiatives— —Mr. Price to focus on market development and penetration— SUNNYVALE, Calif., Nov. 19, 2024 (GLOBE NEWSWIRE) -- CeriBell, Inc. (NASDAQ:CBLL), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions ("Ceribell"), today announced the appointments of Kristie Rodenbush as Chief People Officer and Brian Price as Senior Vice President of Marketing to its leadership team. "Ms. Rodenbush and Mr. Price bring an impressive wealth of experience to Ceribell, and I am confident that their leadership across our People & Culture and Marketing fu

      11/19/24 8:00:00 AM ET
      $CBLL
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care